A Phase II Study of Pembrolizumab in EGFR-mutant, PD-L1+, Tyrosine Kinase Inhibitor (TKI) Naïve Patients with Advanced NSCLC

BACKGROUND: Despite the significant antitumor activity of pembrolizumab in non-small cell lung cancer (NSCLC), clinical benefit has been less frequently observed in patients whose tumors harbor epidermal growth factor receptor (EGFR) mutations compared to EGFR wild-type patients. Our single center e...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:J Thorac Oncol
Hlavní autoři: Lisberg, A, Cummings, A, Goldman, JW, Bornazyan, K, Reese, N, Wang, T, Coluzzi, P, Ledezma, B, Mendenhall, M, Hunt, J, Wolf, B, Jones, B, Madrigal, J, Horton, J, Spiegel, M, Carroll, J, Gukasyan, J, Williams, T, Sauer, L, Wells, C, Hardy, A, Linares, P, Lim, C, Ma, L, Adame, C, Garon, EB
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6063769/
https://ncbi.nlm.nih.gov/pubmed/29874546
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.03.035
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky